Table 1.

Characteristics of study subjects

	n	Age (years)	Male (n)	BMI (kg/m2)	HR (bpm)	LVEF (%)	LV mass index (g/m2)	LV Wallmin (mm)	LV Wallmax (mm)
Patients with normal CMR	70	48 ± 17	45	24 ± 3	65 ± 13	66 ± 9	56 ± 14	7 ± 1	10 ± 2
Cardiac Amyloidosis (AL)	32	73 ± 11	11	28 ± 5	73 ± 13	55 ± 15a	111 ± 32	12 ± 4	18 ± 3a
Cardiac Amyloidosis (ATTR)	22	75 ± 13	14	26 ± 4	79 ± 19	53 ± 14	120 ± 16	12 ± 3	20 ± 5
Anderson-Fabry diseaseb	21	50 ± 17	20	27 ± 5	62 ± 14	60 ± 15	62 ± 25	8 ± 2	13 ± 5
Aortic Stenosis	24	63 ± 18	19	29 ± 7	73 ± 13	62 ± 13	83 ± 23	9 ± 3	14 ± 3
Atrial Fibrillationb	23	66 ± 11	18	28 ± 4	89 ± 19	50 ± 13a	61 ± 13	7 ± 1	11 ± 2
Chronic CAD	309	62 ± 12	193	28 ± 5	69 ± 14	50 ± 16a	74 ± 23	7 ± 2	12 ± 3
Dilated Cardiomyopathy	151	60 ± 15	98	27 ± 7	72 ± 15	35 ± 14a	81 ± 29	5 ± 2a	8 ± 2
Hypertrophic Cardiomyopathy	185	56 ± 15	138	29 ± 11	68 ± 12	69 ± 12	88 ± 33	9 ± 3	19 ± 4a
Hypertension	59	62 ± 14	42	29 ± 5	68 ± 15	61 ± 16	83 ± 38	9 ± 2	14 ± 3
Cardiac Iron-Overloadb	23	53 ± 21	17	23 ± 9	77 ± 14	65 ± 13	56 ± 27	7 ± 2	14 ± 3
Myocarditis (acute)	146	41 ± 12a	68	27 ± 5	75 ± 13	58 ± 13	69 ± 18	8 ± 2	12 ± 2
Myocarditis (previous)	93	47 ± 17	72	27 ± 4	69 ± 14	61 ± 10	62 ± 17	7 ± 1	11 ± 2
Obesity	38	53 ± 15	22	35 ± 4a	70 ± 14	60 ± 10	60 ± 21	7 ± 1	10 ± 2
Pheochromocytoma	29	50 ± 14	14	25 ± 6	71 ± 29	65 ± 10	57 ± 12	8 ± 1	10 ± 1
Cardiac Sarcoidosis	21	59 ± 9	10	28 ± 6	74 ± 13	60 ± 14	64 ± 20	8 ± 2	13 ± 3
Takotsubo cardiomyopathy	45	64 ± 12	35	25 ± 5	74 ± 18	60 ± 15	58 ± 17	8 ± 1	11 ± 3

All values are n (%) or mean ± SD. ARVC arrhythmogenic right ventricular cardiomyopathy, BPM beats per minute, BMI body mass index, CAD coronary artery disease, g gram, HR heart rate, kg kilograms, LVEF left ventricular ejection fraction, LV left ventricular, m metre, mm millimetre, Max maximum, Min minimum

^adenotes values significantly different from patients with normal CMR (all p < 0.05)

^bindicates material from extended analysis period included to address peer review